Parsaclisib, a PI3Kδ inhibitor, in relapsed and refractory mantle cell lymphoma (CITADEL-205): a phase 2 study-Reference-Cited by-同舟云学术

Parsaclisib, a PI3Kδ inhibitor, in relapsed and refractory mantle cell lymphoma (CITADEL-205): a phase 2 study

Published:2023-08 Issue: Volume:62 Page:102131
ISSN:2589-5370
Container-title:eClinicalMedicine
language:en
Short-container-title:eClinicalMedicine

Author:

Zinzani Pier Luigi,Trněný Marek^ORCID,Ribrag Vincent,Zilioli Vittorio Ruggero,Walewski Jan,Christensen Jacob Haaber,Delwail Vincent,Rodriguez Guillermo,Venugopal Parameswaran,Coleman Morton,Dartigeas Caroline,Patti Caterina,Pane Fabrizio,Jurczak Wojciech^ORCID,Taszner Michal,Paneesha Shankara^ORCID,Zheng Fred,DeMarini Douglas J.,Jiang Wei,Gilmartin Aidan,Mehta Amitkumar

Funder

Incyte

Publisher

Elsevier BV

Subject

General Medicine

Reference41 articles.

1. New insights into the epidemiology of non-Hodgkin lymphoma and implications for therapy;Chihara;Expert Rev Anticancer Ther,2015

2. Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Dreyling;Ann Oncol,2017

3. B-cell lymphomas;National Comprehensive Cancer Network,2021

4. Mantle cell lymphoma: 2017 update on diagnosis, risk-stratification, and clinical management;Vose;Am J Hematol,2017

5. Patterns of survival in patients with recurrent mantle cell lymphoma in the modern era: progressive shortening in response duration and survival after each relapse;Kumar;Blood Cancer J,2019

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeted Therapies in the Treatment of Mantle Cell Lymphoma;Cancers;2024-05-20

2. Safety and efficacy of parsaclisib in combination with rituximab, bendamustine + rituximab, or ibrutinib in patients with previously treated B-cell lymphoma: analysis of a phase 1 dose-finding study (CITADEL‑112);Leukemia & Lymphoma;2024-04-10

3. Crystal structure of (S)-5-(3-acetyl-5-chloro-2-ethoxy-6-fluorophenyl)-2-oxazolidinone;Acta Crystallographica Section E Crystallographic Communications;2024-03-19

4. A phase 2 study of the PI3Kδ inhibitor parsaclisib in relapsed and refractory marginal zone lymphoma (CITADEL-204);Blood Advances;2023-12-19